Grace Therapeutics, Inc.

NasdaqCM:GRCE Stock Report

Market Cap: US$38.6m

Grace Therapeutics Management

Management criteria checks 2/4

Grace Therapeutics' CEO is Prashant Kohli, appointed in Apr 2023, has a tenure of 3.25 years. total yearly compensation is $1.07M, comprised of 46.5% salary and 53.5% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $50.61K. The average tenure of the management team and the board of directors is 3.2 years and 3.1 years respectively.

Key information

Prashant Kohli

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage46.53%
CEO tenure3.3yrs
CEO ownership0.1%
Management average tenure3.2yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Analysis Article • Jun 06

We're Keeping An Eye On Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 19

Companies Like Grace Therapeutics (NASDAQ:GRCE) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 02

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 20

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 14

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 10

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma press release (NASDAQ:ACST): Q1 GAAP EPS of -$0.10. Cash, cash equivalents and short-term investments of $38.4M. Given certain cost savings and overall efficiencies implemented across the organization, management believes that it now has sufficient capital to fund operations through at least March 2024, allowing for the advancement of GTX-104 through Phase 3 and advancing GTX-102 and GTX-101 to key value inflection points. The company remains on track to initiate the PK bridging study of GTX-102 in the third calendar quarter of 2022 and is expected to report out topline results on schedule before the end of calendar 2022. Assuming the PK bridging study meets its primary endpoint, and based on the FDA’s subsequent guidance, the Company plans to conduct a Phase 3 safety and efficacy trial in Ataxia Telangiectasia (A-T) patients. The Phase 3 study is expected to be initiated in the second half of calendar 2023.

CEO Compensation Analysis

How has Prashant Kohli's remuneration changed compared to Grace Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$8m

Dec 31 2025n/an/a

-US$6m

Sep 30 2025n/an/a

-US$8m

Jun 30 2025n/an/a

-US$10m

Mar 31 2025US$1mUS$500k

-US$10m

Dec 31 2024n/an/a

-US$13m

Sep 30 2024n/an/a

-US$12m

Jun 30 2024n/an/a

-US$11m

Mar 31 2024US$988kUS$400k

-US$13m

Dec 31 2023n/an/a

-US$39m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$42m

Mar 31 2023US$512kUS$379k

-US$42m

Dec 31 2022n/an/a

-US$17m

Sep 30 2022n/an/a

-US$17m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022US$655kUS$141k

-US$10m

Compensation vs Market: Prashant's total compensation ($USD1.07M) is above average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Prashant's compensation has increased whilst the company is unprofitable.

CEO

Prashant Kohli (54 yo)

3.3yrs
Tenure
US$1,074,621
Compensation

Mr. Prashant Kohli was Vice President of Commercial Operations at Grace Therapeutics, Inc from August 2021 to August 2022. He served as Chief Commercial Officer at Acasti Pharma Inc. from September 2022 un...

Leadership Team

NamePositionTenureCompensationOwnership
Prashant Kohli
CEO & Director3.3yrsUS$1.07m0.13%
$ 50.6k
Amresh Kumar
VP of Program Management3.2yrsUS$421.56k0.068%
$ 26.4k
Carrie D'Andrea
Consultantless than a yearUS$421.56k0%
$ 0
Robert DelAversano
VP of Finance and Principal Financial & Accounting Officer2.7yrsno datano data
R. MacDonald
Member of Scientific Advisory Board & Chief Medical Officer3.2yrsno datano data
3.2yrs
Average Tenure
54yo
Average Age

Experienced Management: GRCE's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Prashant Kohli
CEO & Director2.8yrsUS$1.07m0.13%
$ 50.6k
R. MacDonald
Member of Scientific Advisory Board & Chief Medical Officer4.2yrsno datano data
Edward Neugeboren
Independent Director2.8yrsUS$75.07k0.23%
$ 89.8k
A. Davis
Independent Director2.8yrsUS$83.07k0%
$ 0
Vimal Kavuru
Independent Chairman4.9yrsUS$116.07k8.21%
$ 3.2m
S. Kottayil
Director2.8yrsUS$61.07k2.28%
$ 877.7k
Andrew Ducruet
Member of Scientific Advisory Board4.2yrsno datano data
Alex Choi
Member of Scientific Advisory Board4.5yrsno datano data
W. Kimberly
Member of Scientific Advisory Board3.1yrsno datano data
Alejandro Rabinstein
Member of Scientific Advisory Board3.1yrsno datano data
Sherry Chou
Member of Scientific Advisory Board3.1yrsno datano data
3.1yrs
Average Tenure
58yo
Average Age

Experienced Board: GRCE's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:03
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Grace Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Douglas LoeCantor Fitzgerald Canada Corporation